Ionizable Lipid Nanoparticle Patents: Leaders & White Space 2026
A data-backed look at ionizable lipid nanoparticle patents: 3,467 records, filing concentration among leading assignees, an 83% filing growth from 2021 to 2024, and the IPC branches that remain under-claimed.
Filing growth = 2021 (370 records) → 2024 (678); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 3,467 records in scope (CR5), not the ranked leaders only.
A field built on nucleic-acid delivery, concentrated at the top
Ionizable lipid nanoparticles are the delivery mechanism behind most clinical-stage mRNA and nucleic-acid therapeutics, and the patent record reflects that: 3,467 published records sit within this dataset, running from 2015 through the current data cut-off. Filing is not evenly spread — the top 5 assignees combined hold 31.1% of all records, and the top 10 reach 41.2%, meaning a newcomer’s freedom-to-operate analysis has to start with a small set of dominant filers rather than a broad field of equals. Growth has been sharp rather than steady: filings rose 83% between 2021 and 2024, the last window with reasonably complete publication data, after peaking so far at 752 filings in 2023.
The technology composition confirms where the claim density sits. Nearly every record carries an A61K medicinal-preparations classification, and 40.4% also carry C12N for microorganisms and genetic engineering — the fingerprint of nucleic-acid cargo delivery as the field's commercial core. Chemistry-side branches such as C07C, C07K and C07D each sit in the 11–16% range, while nanotechnology-specific (B82Y) and polymer-chemistry (C08G) approaches remain comparatively thin at 5.0% and 1.8% of records respectively — the branches worth checking first for open claim territory.
Filing concentration, growth and technology composition
3,467 published records make up this dataset, spanning receiving offices from WIPO and the USPTO through EPO, Australia, Canada and Israel. The figures below describe where filing has concentrated and which technology branches carry the claim density.
Filing trend: a threefold rise from 2021 to the 2023 peak
Filings ran at 91 in 2017 and climbed to a peak of 752 in 2023. Between 2021 and 2024 — the last year that can be treated as complete, since publication lags filing by roughly 18 months — filings rose from 370 to 678, a growth of 83%. 2025 and 2026 figures will keep filling in as later applications publish.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
Technology composition: nucleic-acid cargo dominates, polymer chemistry is thin
A61K medicinal preparations sits on 99.6% of the 3,467 records, effectively a baseline tag for this field. C12N (microorganisms and genetic engineering) at 40.4% and A61P (therapeutic activity) at 36.5% mark the nucleic-acid delivery core. C07C, C07K and C07D each sit in the 11–16% range as chemistry-side branches, while B82Y nanotechnology (5.0%) and C08G condensation polymers (1.8%) remain comparatively unclaimed.
Shares are the percentage of the 3,467 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Lipid-Nanoparticle Delivery: Ionizable Lipid Nanoparticle Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about lipid-nanoparticle delivery: ionizable lipid nanoparticle patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe records shaping this landscape
Biomolecule conjugated lipid nanoparticles (WO2025232812A1)
The filing describes a biomolecule-conjugated lipid nanoparticle built from a VHH-linker conjugate joined to an anchor-modified LNP through a bio-orthogonal click reaction between a linker moiety and a matching anchor fragment. The construct is aimed at nucleic-acid delivery vectors that carry a targeting nanobody fragment attached to the LNP surface via defined linker and hinge chemistry.Filed by Shanghai Vitalgen Biopharma, published 2025-11-13 — illustrates the shift from base lipid/cargo claims toward surface-conjugation and targeting chemistry.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2015164674A1 | Nucleic acid vaccines | 447 |
| 2 | WO2017218704A1 | Stabilized formulations of lipid nanoparticles | 321 |
| 3 | US20180028664A1 | Compositions and methods for delivery of agents | 302 |
| 4 | US20130115274A1 | Method of producing lipid nanoparticles for drug delivery | 208 |
| 5 | WO2013093648A2 | Method of producing lipid nanoparticles for drug delivery | 208 |
| 6 | US20150050354A1 | Modified polynucleotides for the treatment of otic diseases and conditions | 198 |
| 7 | WO2018232357A1 | RNA formulations | 181 |
| 8 | US20060083781A1 | Functionalized solid lipid nanoparticles and methods of making and using same | 179 |
| 9 | US9872900B2 | Nucleic acid vaccines | 178 |
| 10 | US10207010B2 | Compositions and methods for delivery of agents | 152 |
Ranked by citation count within the searched corpus; citation counts favor older records and should be read as a signal of influence, not current importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing data says about this field
Beyond the raw counts, a few patterns matter for anyone deciding where to file or where risk concentrates.
A small group of filers set the terms
The leading assignee alone holds 650 records, and the top 5 combined account for 31.1% of all 3,467 records in scope, with the top 10 reaching 41.2%. New entrants are filing into a claim space where core composition and formulation ground is already occupied by a handful of players.
Growth tracks the shift to commercial-scale mRNA delivery
Filings rose from 370 in 2021 to 678 in 2024, having peaked so far at 752 in 2023. The most recent two years will keep revising upward as pending applications publish, given the typical 18-month lag.
Nucleic-acid cargo is the dominant technical thesis
Alongside a near-universal A61K medicinal-preparations tag (99.6%), 40.4% of records also carry C12N for microorganisms and genetic engineering, and 36.5% carry A61P for therapeutic activity — confirming nucleic-acid delivery as the field's commercial center of gravity.
Polymer and nanotech branches remain thin
B82Y nanotechnology applications (5.0%) and C08G condensation polymers (1.8%) sit far below the field's chemistry-heavy branches, marking territory with materially less prior art to search against or design around.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to lipid-nanoparticle delivery: ionizable lipid nanoparticle patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Massachusetts Institute of Technology (MIT) | FUJIFILM Corporation | 23 |
| The Trustees of the University of Pennsylvania | George Mason University | 17 |
| The University of British Columbia | Integrated Nanotherapeutics Inc. | 12 |
| The University of British Columbia | Ludwig Maximilian University of Munich | 11 |
| Massachusetts Institute of Technology (MIT) | Orna Therapeutics, Inc. | 11 |
| The University of British Columbia | VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION INC | 9 |
| Renagade Therapeutics Management Inc. | Orna Therapeutics, Inc. | 8 |
| ModernaTX, Inc. | Oregon State University | 7 |
Only 10 co-assignee pairs appear in the dataset, and the strongest pairings link specific university and industry partners rather than spreading broadly across the field — a sign that most LNP patent work is filed by a single owner rather than jointly.
Turning this landscape into a filing or freedom-to-operate decision
The figures above show where claim density and white space sit today. Turning that into a specific filing strategy or a design-around means going deeper into the individual claim sets behind the leading assignees' filings.
Check a specific claim against the leaders' portfolios
Run the composition or formulation claim you're considering against the filings held by the top 5 assignees, who together hold 31.1% of all 3,467 records in scope.
Search claims in EurekaTrack the underclaimed branches as they fill in
B82Y and C08G filings are still thin relative to the rest of the field — worth monitoring as later 2025–2026 publications continue to land.
Set up monitoring in EurekaMap co-assignee routes into adjacent claim space
With only 10 co-assignee pairs on record, partnering patterns are identifiable and worth reviewing before choosing a filing partner.
Explore assignee networks in EurekaCommon questions on the ionizable lipid nanoparticle patent landscape
The assignee ranking covers 100 companies drawn from 3,467 published records, and filing is heavily concentrated at the top: the leading assignee alone holds 650 records, and the top 5 combined account for 31.1% of all records in scope. The top 10 combined reach 41.2% of the field. This means a small group of pharmaceutical and biotech filers, several with university co-assignees, control a disproportionate share of the claim space, while the remaining 90 ranked companies hold much smaller, more specialized filing positions.
Filings rose from 370 in 2021 to 678 in 2024, an increase of 83% over that three-year span — the most recent period that can be treated as reasonably complete given an 18-month publication lag. The field peaked so far at 752 filings in 2023. Figures for 2025 and 2026 will continue to rise as pending applications publish, so they should not yet be read as a slowdown.
Nearly all records (99.6%) carry an A61K medicinal-preparations classification, reflecting the pharmaceutical framing common to the field. Within that, 40.4% of records also carry a C12N classification for microorganisms and genetic engineering, and 36.5% carry A61P for therapeutic activity, marking nucleic-acid cargo delivery as the dominant technical thrust. Smaller shares cover specific chemistries: C07C and C07K each sit around 16%, C07D at 11.2%, and nanotechnology (B82Y) and polymer chemistry (C08G) trail at 5.0% and 1.8% respectively.
Risk concentrates wherever claim density is highest, which the evidence points to as core ionizable-lipid composition and nucleic-acid LNP formulation, held disproportionately by the leading assignee and the rest of the top 5 filers (31.1% of all 3,467 records). The most-cited records, including WO2015164674A1 and WO2017218704A1, anchor foundational formulation and stabilization claims that later filers have needed to file around. Anyone entering this space should expect the densest prior art around base lipid composition and stabilized formulation, with comparatively less occupied ground in nanotechnology-specific and polymer-based delivery routes.
Yes, in the technology branches with the lowest record share. B82Y nanotechnology applications sit at only 5.0% of the 3,467 records, and C08G condensation polymers at just 1.8%, both far below the near-universal A61K baseline. These branches represent claim territory where far fewer filings exist to search against or design around. That said, thin filing density does not by itself guarantee patentability — it means less prior art has been mapped there, not that the underlying chemistry is unclaimed elsewhere under different classification.
Research Lipid-Nanoparticle Delivery: Ionizable Lipid Nanoparticle Patent Landscape in depth with Eureka
Go past this page: query the whole lipid-nanoparticle delivery: ionizable lipid nanoparticle patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.